SA Asks: Is Moderna's stock now a sell after the recent run-up? (MRNA:NASDAQ)
· seekingalpha.com
Moderna's (MRNA) stock surged on cancer vaccine hype, but analysts warn sales forecasts and valuation are stretched ahead of key trial readouts. Read more here.
Shares of Moderna (MRNA) have rallied 202% since Aug. 18, fueled by positive news about the biotech company's experimental cancer vaccine, intismeran, which is ...